氟桂利嗪该怎么用?有哪些注意事项?超全用法总结来了!

2022-05-10 网络 网络

盐酸氟桂利嗪是临床上常用的抗眩晕药,属于钙通道阻断剂,主要通过阻滞过量的钙离子跨膜进入细胞内

盐酸氟桂利嗪是临床上常用的抗眩晕药,属于钙通道阻断剂,主要通过阻滞过量的钙离子跨膜进入细胞内,抑制钙超载而造成的细胞损害,能够持久抑制血管痉挛,对基底动脉和颈内动脉尤为明显,改善脑微循环和神经元代谢,并可增加耳蜗小动脉血流量,改善前庭器官循环,防止神经细胞阵发性去极化和细胞放电,具有抗癫痫作用,还能明显减轻缺血性心肌损害,保护心肌细胞,具有较高脂溶性,易透过血脑屏障,在临床上主要用于眩晕症的治疗和偏头痛的预防性治疗,还可用于耳鸣和癫痫症的辅助治疗。

 

图片

临床适应症及用法用量

图片
1.脑循环障碍
脑供血不足,脑血栓形成后等。脑动脉硬化,脑梗塞恢复期;氟桂利嗪每日5~10mg
2.椎动脉缺血
包括椎基地底动脉供血不全在内的中枢性眩晕及外周性眩晕,选用氟桂利嗪每日10~20mg,2~8周为1疗程。
3.耳鸣、脑晕

对于眩晕症患者,氟桂利嗪的服用方法为:65岁以下起始剂量为10mg/天(2粒),65岁以上起始剂量为5mg/天(1粒),睡前服用,疗程一般不超过2个月,对于慢性眩晕症患者,如果用药1个月后症状没有改善,说明对药物反应不佳,可以停药,对于突发性眩晕症患者,如果用药2个月后症状没有改善,可以停药,严格遵医嘱用药,不要随意增加剂量或延长用药时间。

特发性耳鸣者,氟桂利嗪10mg,每晚1次,10天为一个疗程。
4.预防偏头痛

对于偏头痛患者,氟桂利嗪的服用方法为:65岁以下起始剂量为10mg/天(2粒),65岁以上起始剂量为5mg/天(1粒),睡前服用,待症状控制后进行维持治疗,维持治疗连续服药5天,停药2天,维持6个月,才能停药,以防复发,如果用药2个月后症状改善不明显,说明对药物反应不佳,可以停药,严格遵医嘱用药,不要随意增加剂量或延长用药时间。

5.间歇性跛行
每日10~20mg
6.癫痫的辅助治疗
可阻断钙超载而防止阵发性去极化,细胞放电,从而避免癫痫发作
 
图片
图片

不良反应及注意事项

图片

不良反应
 
1.中枢神经系统的不良反应
嗜睡和疲惫感为最常见。长期服用者可以出现抑郁症,以女性病人较常见。椎体外系症状,表现为运动徐缓,静坐不能,下颔运动障碍,震颤,强直等。多数用药3周后出现,停药后消失。老年人中容易发生。少数病人可出现失眠,焦虑等症状。 
 
2.消化道症状
胃部烧灼感,胃纳亢进,进食量增加,体重增加。
 
3.其他
少数病人可出现皮疹,口干,溢乳,肌肉酸痛等症状。这些症状,多数为短暂性。
注意事项
1.与酒精、催眠药或镇静药合用时,加重镇静作用。
2.与苯妥英钠,卡马西平联合应用时,可以降低氟桂利嗪的血药浓度。 
3.放射治疗病人与氟桂利嗪联合应用时,可提高对肿瘤细胞的杀伤力。 
4.在应用抗癫痫药物治疗的基础上加用氟桂利嗪可以提高抗癫痫效果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906783, encodeId=88471906e83f5, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat May 21 00:56:56 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218640, encodeId=75ac121864014, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed May 11 07:09:30 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218639, encodeId=634912186394e, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:43 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218632, encodeId=414c1218632ac, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed May 11 06:28:34 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906783, encodeId=88471906e83f5, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat May 21 00:56:56 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218640, encodeId=75ac121864014, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed May 11 07:09:30 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218639, encodeId=634912186394e, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:43 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218632, encodeId=414c1218632ac, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed May 11 06:28:34 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-05-11 xulv123

    认真学习~~

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1906783, encodeId=88471906e83f5, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat May 21 00:56:56 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218640, encodeId=75ac121864014, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed May 11 07:09:30 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218639, encodeId=634912186394e, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:43 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218632, encodeId=414c1218632ac, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed May 11 06:28:34 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906783, encodeId=88471906e83f5, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat May 21 00:56:56 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218640, encodeId=75ac121864014, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed May 11 07:09:30 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218639, encodeId=634912186394e, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Wed May 11 07:04:43 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218632, encodeId=414c1218632ac, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed May 11 06:28:34 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-05-11 学医无涯

    学习一下

    0